THONBURI HEALTHCARE GROUP PUBLIC COMPANY LIMITEDSET: THG🇹🇭 TH

Board Performance · 2025

Compliance Monitoring — Overview

Compliance Monitoring — Introduction

Monitoring to ensure compliance with corporate governance policies and practices.

The Board of Directors believes that good corporate governance will make the group’s operations efficient, transparent and fair to all stakeholders. It will help in building credibility, increasing competitiveness for the group, and creating stability and sustainable growth to the Company. Therefore, there is a corporate governance Handbook. The Corporate Governance and Sustainability Committee plays a role in supervising the group's policies and guidelines for good corporate governance and business ethics to be in accordance with international standards. and the relevant policies are reviewed at least once a year.

In December 2025, the Company informed all directors, executives, and employees of its corporate governance policy, various important corporate governance-related policies and practices, and business ethics, which have been consolidated in the Company’s Corporate Governance Handbook, 8th Revised Edition (“Corporate Governance Handbook”), which was reviewed and approved by the Board of Directors' Meeting No. 14/2025 held on 12 November 2025, including the “Anti-Corruption Policy and Guidelines”, to all directors, executives, and employees for acknowledgement and understanding through completing an assessment and signing an acknowledgement of compliance with the policies in the said Corporate Governance Handbook via an online platform ('Google Form') with 100% completion, to ensure that everyone is aware of, understand, and will comply with the corporate governance policies and practices throughout the organization, as well as published on the Company's website.

The Board of Directors has determined that it is a responsibility of all directors, executives, and employees to be informed and comply with the policy and requirements under the Company's corporate governance manual. The Corporate Governance and Sustainability Committee has assigned the Corporate Governance and Sustainability working group to monitor and coordinate with the group and report on compliance with such policy on a regular basis. In the past year, compliance with good corporate governance according to the manual has been comprehensively monitored in areas such as respecting the rights of shareholders, equal treatment of all stakeholders, information disclosure and transparency, responsibilities of the Board of Directors, caring for the environment, support on new innovations, and anti-corruption etc. It was found that the Company has fully complied with guidelines in each issue and has been assessed by the relevant agencies as follows:

  • The Company received the full assessment score at 100 under the quality assessment program by the Thai Investors Association for arrangement of the 2025Annual General Meeting of Shareholders.

  • The Company received a corporate governance assessment for the year 2025 at the "Good" level (Good CG Scoring)" or 3-star symbol level in the Corporate Governance Report of Thai Listed Companies (CGR) project from the Thai Institute of Directors Association.

Monitoring of Compliance with Other CG Policies & Guidelines

Monitoring to ensure compliance with corporate governance policies and practices.    

    The Board of Directors believes that good corporate governance will make the group’s operations efficient, transparent and fair to all stakeholders. It will help in building credibility, increasing competitiveness for the group, and creating stability and sustainable growth to the Company. Therefore, there is a corporate governance Handbook. The Corporate Governance and Sustainability Committee plays a role in supervising the group's policies and guidelines for good corporate governance and business ethics to be in accordance with international standards. and the relevant policies are reviewed at least once a year.

    In December 2025, the Company informed all directors, executives, and employees of its corporate governance policy, various important corporate governance-related policies and practices, and business ethics, which have been consolidated in the Company’s Corporate Governance Handbook, 8th Revised Edition (“Corporate Governance Handbook”), which was reviewed and approved by the Board of Directors' Meeting No. 14/2025 held on 12 November 2025, including the “Anti-Corruption Policy and Guidelines”, to all directors, executives, and employees for acknowledgement and understanding through completing an assessment and signing an acknowledgement of compliance with the policies in the said Corporate Governance Handbook via an online platform ('Google Form') with 100% completion, to ensure that everyone is aware of, understand, and will comply with the corporate governance policies and practices throughout the organization, as well as published on the Company's website.

    The Board of Directors has determined that it is a responsibility of all directors, executives, and employees to be informed and comply with the policy and requirements under the Company's corporate governance manual. The Corporate Governance and Sustainability Committee has assigned the Corporate Governance and Sustainability working group to monitor and coordinate with the group and report on compliance with such policy on a regular basis. In the past year, compliance with good corporate governance according to the manual has been comprehensively monitored in areas such as respecting the rights of shareholders, equal treatment of all stakeholders, information disclosure and transparency, responsibilities of the Board of Directors, caring for the environment, support on new innovations, and anti-corruption etc. It was found that the Company has fully complied with guidelines in each issue and has been assessed by the relevant agencies as follows:

  • The Company received the full assessment score at 100 under the quality assessment program by the Thai Investors Association for arrangement of the 2025Annual General Meeting of Shareholders.

  • The Company received a corporate governance assessment for the year 2025 at the "Good" level (Good CG Scoring) or 3-star symbol level in the Corporate Governance Report of Thai Listed Companies (CGR) project from the Thai Institute of Directors Association.

Prevention of Conflicts of Interest

Has the Company Acted to Prevent Conflicts of Interest?

Yes

Operations in the Past Year

Prevention of conflicts of interest

The Company has a policy to prevent and eliminate conflicts of interest that may arise in the future. The policy is also used to consider any connected transaction by the Company and/or its subsidiaries with person who may have conflict of interest to be in accordance with the relevant rules, regulations and laws.

  1. The Company’s directors and executives have prepared report on conflict of interest as prescribed by the SET to report on the interest of himself and related persons.

  2. Clarifications on position as director and major shareholder in the same business without conflict of interest with THG

    2.1)   Mr. Paiboon Eksaengsri, (M.D.), Director and Group Chief Executive Officer

            The Board of Directors’ Meeting No. 19/2024, held on 17 October 2024, having considered the suggestions and recommendations of the Nomination and Remuneration Committee, resolved to approve the appointment of Mr. Paiboon Eksaengsri, (M.D.), a Director of the Company, as Group Chief Executive Officer, effective from 1 November 2024 onwards. The Board of Directors is of the opinion that Mr. Paiboon Eksaengsri, (M.D.) is a person with knowledge, capabilities, skills, and experience in management and business operations that align with THG's business. He has specialized expertise that benefits THG's business and is consistent with its business strategy. He possesses integrity and business ethics, demonstrates strong leadership, has a broad vision, moral principles and ethics, as well as a positive attitude toward the organization. He has a transparent work history and does not have any prohibited characteristics under the Public Limited Companies Act B.E. 2535 (as amended) and related laws.

            In this regard, the Board of Directors’ Meeting No. 2/2026, held on 23 February 2026, having considered the suggestions and recommendations of the Nomination and Remuneration Committee, reviewed the matter that Mr. Paiboon Eksaengsri, (M.D.), holds directorship positions in the following companies: 1) Vibharam Samutprakarn Hospital Co., Ltd., 2) Synphaet Kanchanaburi Co., Ltd., 3) Synphaet Thepharak Co., Ltd., 4) Vibharam (Amata Nakorn) Hospital Co., Ltd., 5) Songsamphan Co., Ltd., 6) Synphaet Seriruk Co., Ltd., 7) Vibharam Hospital Co., Ltd., and 8) Vibharam-Pakkred Hospital Co., Ltd. These companies operate in the medical services business and are group companies and/or affiliated hospitals under the management of Ramkhamhaeng Hospital Public Company Limited (“RAM”) or its subsidiaries. The hospitals are located in the eastern region, particularly within the Eastern Economic Corridor (EEC), as well as in the northern and northeastern regions of Thailand. Therefore, the service areas of the group companies and/or affiliated hospitals under RAM are geographically diversified, with no overlap, and do not compete directly in terms of medical service coverage of the affiliated hospitals under THG. The shareholders have acknowledged the non-competition arrangement between RAM group and THG group, as detailed in the documents for the Extraordinary General Meeting of Shareholders No. 1/2025, held on 9 June 2025. In addition, on 5 August 2025, the Trade Competition Commission of Thailand (OTCC) approved the application for the merger between RAM and THG.

    Therefore, the appointment of Mr. Paiboon Eksaengsri, (M.D.), as a director and Group Chief Executive officer of THG is not in conflict with the Public Limited Companies Act B.E. 2535 (1992) and other relevant laws which prohibits a director from engaging in a business of the same nature as, and in competition with the business of the company, or from serving as a director of a private company or any other company that operates a business of the same nature as, and in competition with the business of the company.

    2.2) Directors who are representatives from the major shareholder, Ramkhamhaeng Hospital Public Company Limited (“RAM”), totaling 3 persons, namely, 1. Dr. Rukkagee kanjanapitak; 2. Mr.Siripong Luengvarinkul, (M.D.); and 3. Mr.Pramuk Unachak, (M.D.)

        Ramkhamhaeng Hospital Public Company Limited (“RAM”) and group companies and/or affiliated hospitals under the management of RAM or its subsidiaries operate in the medical services business, located in the eastern region, particularly within the Eastern Economic Corridor (EEC), as well as in the northern and northeastern regions of Thailand. Therefore, the service areas of the group companies and/or affiliated hospitals under RAM are geographically diversified, with no overlap, and do not compete directly in terms of medical service coverage of the affiliated hospitals under THG. The shareholders have acknowledged the non-competition arrangement between RAM group and THG group, as detailed in the documents for the Extraordinary General Meeting of Shareholders No. 1/2025, held on 9 June 2025. In addition, on 5 August 2025, the Trade Competition Commission of Thailand (OTCC) approved the application for the merger between RAM and THG.

    RAM has proposed to the Board of Directors and/or the Shareholders’ Meeting to consider appointing the representatives of RAM, totaling 3 persons, namely, 1. Dr. Rukkagee Kanjanapitak; 2. Mr.Siripong Luengvarinkul, (M.D.); and 3. Mr.Pramuk Unachak, (M.D.), to be directors of THG. This is not in conflict with the Public Limited Companies Act B.E. 2535 (1992) and other relevant laws which prohibits a director from engaging in a business of the same nature as, and in competition with the business of the company, or from serving as a director of a private company or any other company that operates a business of the same nature as, and in competition with the business of the company.

    In this regard, for any agenda item in which RAM has an interest (connected transaction), it is determined that 3 representative directors of RAM shall abstain from voting on such agenda item.

  1. Disclosure of related party transactions: In 2025, the Company did not have any related party transactions that required approval from the Board of Directors and disclosure of information to the Stock Exchange of Thailand.

Number of Conflict-of-Interest Cases

MetricCurrent YearPrevious YearTwo Years Ago
Total number of cases or issues related to conflicts of interest (cases)000

Prevention of the Use of Inside Information

Has the Company Acted to Prevent the Use of Inside Information?

Yes

Operations in the Past Year

Supervision of the use of inside information

  1. The Company has established a policy on the use of the Company’s inside information to protect employees, executives and directors, and related persons such as auditors from using inside information for securities trading or for personal use. The persons prescribed under the laws must be careful when trading the Company's securities prior to disclosing inside information to the public.

  2. There is a hierarchy of access to confidential information and restrictions on usage.

  3. Directors and executives according to the definitions prescribed by the SEC shall report changes in securities holdings to the SEC Office in accordance with Section 59 f the Securities and Exchange Act B.E. 2535(as amended) and submit a copy of such report to the Company Secretary on the same day as the date of submission of the report to the SEC office every time.

  4. Violators of the use of inside information will be punished according to the laws.

    In the past year, the Company did not find any director, executive, employee or related persons commit any act that is contrary to the Company's policy on using inside information.

However, on 29 December 2025, the Company disclosed to the Stock Exchange of Thailand regarding the acknowledgement of the SEC Notification No. 338/2025, dated Friday, 26 December 2025, in which the SEC filed charges against 14 individuals, including Mrs. Charuvarn Vanasin, a director of the Company, and related persons, to the Economic Crime Suppression Division (ECD), in connection with the manipulation of the share price and/or trading volume of Thonburi Healthcare Group Public Company Limited (THG), and also reported the matter to the Anti-Money Laundering Office (AMLO). The matter mentioned will not have a significant impact on the Company's business operations and policies. At present, Mrs. Charuwan Vanasin and related persons are not directors with authorized signatory power binding the Company in any manner.

    In this regard, the Board of Directors has taken into consideration the matter in which the SEC filed charges against Mrs. Charuwan Vanasin and related persons in connection with the manipulation of the share price and/or trading volume of THG shares, as a factor in deliberating on the expiration of the directorship term of Mrs. Charuwan Vanasin, prior to presenting the matter to the 2026 Annual General Meeting of Shareholders.

Number of Inside-Information Cases

MetricCurrent YearPrevious YearTwo Years Ago
Total number of cases or issues related to the use of inside information to seek benefits (cases)000

Anti-Corruption

Has the Company Acted on Anti-Corruption?

Yes

Operations in the Past Year

Anti-corruption policy

In the past year, the Company has implemented the anti-corruption policy as follows:

  1. The Company has communicated such policy to employees and executives via trainings and circulars. The employees have to review and sign a form to acknowledge such policy and also answer an understanding assessment for 100 percent of employees. The policy is used as part of the new employee orientation content and as part of employee evaluation score. This is a score which comes from taking an organizational exam that contains questions regarding ethics and work practices, including anti-corruption, to educate employees on anti-corruption policy and practices. This also encourages employees to be honest and responsible for the performance of their duties and responsibilities.

  2. The Company has disclosed the anti-corruption policy on its website under the Corporate Governance Manual

Additional Guideline for the Prevention of Involvement in Corruption

    The Company has procured the Internal Audit Department to monitor the internal audit system, risk management and corporate governance and to provide suggestion from time to time by auditing in accordance with the annual internal audit plan which has been approved by the Audit Committee and reporting the result of audit in key issues and suggestion to the Audit Committee.

    The Risk Management Committee has determined the guideline for assessment of risk from internal corruption to determine the anti-internal corruption measure in order for efficient implementation and support of complying with the guideline for monitoring and evaluating the implementation of the anti-corruption policy within the organization including providing the suggestions, control measure or prevention guideline for such risk together with following up the evaluation to improve the plan from time to time to reduce the risk to the acceptable level and reporting it to the Board of Directors regularly.

    The Company has determined the guideline to monitor for prevention and following up of risk on corruption within the organization as follows:

  1. The Company provides channels for receiving clues or complaints regarding violation, illegal actions or business ethics of the Company or doubt in financial report or internal control system.The Company has policy on whistle-blower protection, and it will keep the information of whistle-blower as confidential.The Company also has measure to review and determine the disciplinary actions and/or legal actions.If the Company is able to contact the whistle-blower, the Company will inform its action in writing.

  2. The Company has procured to have internal audit, assessment of internal control system and risk management which cover important working systems to protect and to follow up the risk on corruption including providing the suggestion in relation to the appropriate solution.

  3. If after the fact finding, it finds that the audited information or complaint may have evidence to believe that there have transactions or actions that may significantly impact the financial status and Company’s performance including violation or wrongful actions relating to legal or business ethics of the Company, the Audit Committee shall inform the Board of Directors to carry out improvements within the time frame that the Audit Committee deems appropriate.

  4. The department heads are responsible for monitoring the operations, correction of errors (if any) and report to the authority respectively.

  5. The Company has determined that the managements and employees shall perform and evaluate their performance in relation to the Corporate Governance Handbook including the anti-corruption in the organization policy regularly.

  6. The Company has determined the guideline to follow up the performance assessment in accordance with the guideline for preventing corruption in the organization.

Form of Anti-Corruption Operations

Operation
Review of appropriateness in anti-corruption
Communication and training for employees on anti-corruption policy and guidelines
The monitoring of the evaluation of compliance with the anti- corruption policy

Number of Corruption Cases

MetricCurrent YearPrevious YearTwo Years Ago
Total number of cases or issues related to corruption (cases)000

Whistleblowing

Has the Company Implemented Whistleblowing Procedures?

Yes

Operations in the Past Year

    Whistle Blower Policy

    The Company has given the opportunity to directors, executives, employees and internal and external stakeholders of the Company and its subsidiaries to report suspected illegal acts, complaints or recommendations relating to illegal or unethical acts, incorrectness of financial reports, corruption or deficiency in internal control system of the Company or its subsidiaries. The Company shall investigate and find facts relating to such report, complaint or recommendation in order to determine appropriate measures or actions. Such information can be reported via the following channels:

    In the past year, there was neither complaint nor report of any clue relating to illegal action, including complaint or suggestion relating to legal offense, business ethics, inaccurate financial report, corruption or deficiency in the internal control systems of the Company and its subsidiaries.

    However, the Company received 1 complaint regarding the roles and responsibilities of executives in a subsidiary company, including, for example, inventory management and sales team management, which resulted in a decline in business performance. Based on the fact-finding investigation of the matter, the Company found no significant risk to the business.

    In this regard, the Company has taken corrective action to address the complaint by establishing additional sales-related policies, such as incentive compensation structure and sales target setting, which have been duly implemented. The Company has also enforced strict compliance with such policies and required verification of the accuracy of data and documents prior to the disbursement of any compensation to the sales units.

Number of Whistleblowing Cases

MetricCurrent YearPrevious YearTwo Years Ago
Total number of cases or issues received through whistleblowing channels (cases)110

Details of Whistleblowing Cases

StatusPeriod TypeStart of PeriodEnd of PeriodDetails of the Case or IssueInvestigation ResultsCorrective ActionsCase or Issue
Incident no longer subject to actionWithin (month/year)2025-122025-12
The Company received 1 complaint regarding the roles and responsibilities of executives in a subsidiary company, including, for example, inventory management and sales team management, which resulted in a decline in business performance. Based on the fact-finding investigation of the matter, the Company found no significant risk to the business.
Based on the fact-finding investigation of the matter, the Company found no significant risk to the business.
In this regard, the Company has taken corrective action to address the complaint by establishing additional sales-related policies, such as incentive compensation structure and sales target setting, which have been duly implemented. The Company has also enforced strict compliance with such policies and required verification of the accuracy of data and documents prior to the disbursement of any compensation to the sales units.
3201 · Other name: The roles and responsibilities of executives in a subsidiary company · Description: Other

Selection of Directors & Chief Executives

Selection — Introduction

The Board of Directors has assigned the Nomination and Remuneration Committee with responsibilities on formulating policy, criteria, and methods in nominating the Board of Directors and sub-committees by considering the appropriateness of the number, structure, and composition of the Board of Directors, including determining the qualifications of directors in accordance with the appropriate size, type, and complexity of the business. The Nomination and Remuneration Committee considers, nominates, selects, and proposes individuals possessing appropriate qualifications to assume the position of director and sub-committee member whose term has expired and/or whose position has become vacant and/or for additional appointments, in accordance with applicable regulations and laws, and pursuant to transparent criteria and methodology for nomination and selection. The Nomination and Remuneration Committee consider candidates based on their knowledge, experience, professional expertise, diversity of skills (Board Skills Matrix), and specific qualifications necessary for the conduct of the Company's business, to achieve balance across various fields and to derive maximum benefit. The Nomination and Remuneration Committee may also consider candidates from director lists or databases (Director Pool) maintained by reputable organizations. Nominations shall be submitted to the Board of Directors and/or the shareholders' meeting for consideration and approval, as applicable. In cases the Nomination and Remuneration Committee proposes the re-appointment of a retiring director, it shall consider that director's performance, contribution, and attendance records at the Board of Directors’ meetings, subcommittee meetings (if any), and shareholders' meetings, so that shareholders may use this information as part of their consideration.
In this regard, the Board of Directors has delegated the Nomination and Remuneration Committee to oversee that the Board of Directors’ composition remains appropriate and aligned with changing environments and circumstances. The Board of Directors must consist of individuals with diverse knowledge, capabilities, and experience, and the Nomination and Remuneration Committee shall also review the independence of each independent director to ensure that the Company's independent directors fully meet the required qualifications.
Nomination of Directors

The selection of persons to be nominated as the director and executive of the Company, a nominated person shall have qualifications according to Section 68 of the Public Company Limited Act 1992 and the Company’s Articles of Association and shall not have any characteristics prohibited by the Notification of the Capital Market Supervisory Board No. 28/2008 regarding the request for approval and approval for the offering of newly issued shares dated 15 December 2008. The policy and criteria the nomination and appointment of directors and executives are as follows:

Board of Directors

Qualification of the board of directors: A director must be a person with knowledge and experience which will benefit the business, having honesty, integrity, and ethical business practice, devoting adequate time to apply his/her best knowledge and ability to perform duties for the Company.

1) A director must satisfy all qualifications required, having no prohibited characters as outlined in the Public Company Limited Act 1992 (including the amendment) (" Public Limited Company Act") 1992 (including the amendment) (" Securities Act") and notifications, regulations and/ or relevant rules. He/ she must not possess the character which shows the lack of qualifications to be trusted by the Company in management of the entity where shareholders are the public as described by the Securities and Exchange Commission and the Stock Exchange of Thailand and/ or the Capital Market Advisory Board. He/she must be a person being listed in the database of directors and management board of the listed company as a state in the Capital Market Advisory Board's notification, regarding the criteria of displaying the list of directors and management board of the listed companies.

2) A director cannot engage in a business of the same nature and competes with the Company or become a partner or a director in another juristic person having the same business and is in competition with the Company whether for his/ her own benefit or the others unless such engagement is noticed in the meeting of shareholders prior to the appointment. A director may hold a directorship in another company, under the condition that such a position will not impede his/ her performance in the Company, and that it is in line with the guideline specified by the Securities and Exchange Commission and the Stock Exchange of Thailand.

3) A director shall give notice to the Company without delay if he/ she has an interest in the contract, whether made directly or indirectly by the Company or in case of an increase or decrease of shareholding.

Policy and criteria for selection of director

  1. Selection of new director

    1.1 To consider the appropriation of number, composition, and diversity of the Board of Directors structure by taking into account necessary skills which do not have in the Board of Directors such as professional skill, gender, age, and specialization that are in line with the Company’s business and line with the Company’s strategy for the completeness and strengthen of the Board of Directors composition to lead the Company to achieve the business objectives under the corporate governance principle.

    1.2. To select a qualified person as determined by the laws, regulatory bodies, the Company, and notifications.

    1.3. To select an honorable person who has knowledge, leadership, opinion, and decision-making with information and reason including morals and ethics, and not on the blacklist.

  2. Renewal of retried director by rotation, shall consider the profile and past performance during holding the director position as follows:

    2.1.To review the Company’s information, and meeting agendas and provide an opinion that is beneficial to the Company

    2.2. To dedicate time to the Company and join the activities and meetings

Selection and appointment of director process

In the selection of a director, the Nomination and Remuneration shall perform the followings:

  1. To prepare Board Skill Matrix to determine the qualification of the candidate director under the policy and criteria for selection of director.

  2. To consider a person who has the qualification that is beneficial and appropriate to the nature of the business operation, strategies, and plans and understands the Company’s business in all aspects with transparency as follows:

    2.1. To nominate from the list of qualified persons as proposed in advance by the shareholders in the Annual General Meeting of shareholders which it has notified to the shareholders through the SET portal and the Company’s website.

    2.2. To nominate a person under the database of the IOD Chartered Director

    2.3. To nominate from management in the organization and a person from an external organization who have qualification in accordance with the requirements.

  3. The Nomination and Remuneration Committee shall invite, interview, and discuss with the qualified person according to the requirements to ensure that such a person is willing to be appointed as the director if such person has been appointed by the Board of Directors or the shareholders’ meeting.

  4. The Nomination and Remuneration Committee proposes qualified person according to the selection’s criteria to the Board of Directors for approval of the appointment or for proposing to the shareholders’ meeting for approval of each person by:

    4.1. One shareholder shall be one vote to one share.

    4.2. Each shareholder may use all of its votes as set out in Clause 1 to appoint one person or many persons to be the directors, but the votes cannot be separated.

    4.3. The person who receives the highest vote shall be appointed as the director and any person who receives the vote lower than the first person may be appointed as the director if there have vacancies of director position according to the number of directors to be appointed in such meeting.

    If the number of persons who will be appointed in the second ranking have the equal vote more than the number of directors to be appointed in such meeting, the Chairman of the meeting shall have the final decision.

  5. To appoint the director in accordance with the Company’s Articles of Association.

    If there have vacancy due to other reason other than the retirement by rotation such as resignation. The Nomination and Remuneration Committee shall consider and select the qualified person to propose to the Board of Directors for approval of the appointment of new director in replacement of the retried person within the timeline as required by laws or regulatory bodies. Such person who being a director shall have the term equal to the remaining term of the replaced director.

Directors & Chief Executives — Introduction

Recruitment of Senior Executives as defined by the Office of the SEC

  1. The executives must be knowledgeable, capable, and experienced persons who shall be beneficial to the Company's business operations, honesty, ethics in business operations and time to dedicate knowledge, ability and duty to the Company fully.

  2. The executives must have complete qualifications and no prohibited characteristics under the law governing public limited company, securities and exchange and other laws related to the business of the Company. In addition, there must not be any characteristic that indicates the lack of appropriate to be trusted to manage the business with the public as a shareholder as prescribed by the SEC.

  3. The executives must notify the Company without delay if there is special interest in the contract made by the Company whether directly or indirectly, or to increase or decrease share in the Company or its subsidiaries.

The process of recruiting and appointing executives according to the definitions of the Office of the SEC

The Human Resources Department shall recruit and select qualified, skilled, experienced and knowledgeable people in the right business and then approach that person to ensure that they are willing to take on management positions if already considered and agreed by the authorized person. Then such persons shall be selected by the Nomination and Remuneration Committee before proposing to the Board of Directors for approval.

Are Directors Selected Through the Nomination Committee?

Yes

Are Chief Executives Selected Through the Nomination Committee?

Yes

Directors from Major Shareholders — Introduction

The number of directors representing the major shareholder, Ramkhamhaeng Hospital Public Company Limited (“RAM”), totals three, namely: (1) Dr. Rukkagee Kanjanapitak, (Ph.D.), (2) Mr. Siripong Luengvarinkul, (M.D.), and (3) Mr. Pramuk Unachak, (M.D.).

In this regard, Dr. Aurchat Kanjanapitak resigned from his position as a director of Ramkhamhaeng Hospital Public Company Limited on 7 May 2025 and, therefore, is no longer considered a director representing the major shareholder, RAM.

Number of Directors from Major Shareholders

3

Rights of Minority Shareholders on Director Appointment

The Nomination and Remuneration Committee proposes qualified person according to the selection’s criteria to the Board of Directors for approval of the appointment or for proposing to the shareholders’ meeting for approval of each person by:

  1. One shareholder shall be one vote to one share.

  2. Each shareholder may use all of its votes as set out in Clause 1 to appoint one person or many persons to be the directors, but the votes cannot be separated.

  3. The person who receives the highest vote shall be appointed as the director and any person who receives the vote lower than the first person may be appointed as the director if there have vacancies of director position according to the number of directors to be appointed in such meeting.

If the number of persons who will be appointed in the second ranking have the equal vote more than the number of directors to be appointed in such meeting, the Chairman of the meeting shall have the final decision.

Method of Director Appointment

Method
Method whereby each director requires approval votes more than half of the votes of attending shareholders with voting rights

Selection of Independent Directors

Criteria for Selecting Independent Directors

An independent director shall not act as an executive and shall be independent of the management and shareholders who have controlling power including not having any business relationship with the Company in a manner that will have a limitation on providing an independent opinion. The independent director shall have the qualifications according to the Notification of the Capital Market Supervisory Board as follows:

  1. Hold up to 0.5% of the total voting shares of the Company, parent company, subsidiary companies, associated companies, major shareholders, or controlling persons of the Company. The calculation of shareholding shall include shares held by related persons of the independent director.

  2. Not being or was appointed as a director who involves in business management, employee, an advisor who has a fixed salary or controlling person of the Company, parent company, subsidiary companies, associated companies, sister companies, major shareholders or controlling persons of the Company unless he or she has discharged from such position for not less than two years before being appointed as a member of the Audit Committee. These prohibited characters shall not include independent directors who acted as government officers or advisors of government which is a major shareholders or controlling persons of the Company.

  3. Not being a related person by blood or registration under laws, such as father, mother, spouse, sibling or children or spouses of children of other directors, executives, major shareholders, controlling person, or other persons who will be nominated as director, executive or the person in control of the Company and its subsidiaries.

  4. Not having or had a business relationship with the Company, parent company, subsidiary companies, associated companies, crucial shareholders, or controlling persons of the Company. Which may disturb any expression of independent opinion. Including not being or having been a significant shareholder or controlling person of a person who has a business relationship with the Company, parent company, subsidiary companies, associated companies, crucial shareholders, or persons in control of the Company unless the relationship has ended for not less than two years before being appointed as a member of the Audit Committee. In addition, they shall not have any conflict of interest, whether direct or indirect, concerning the financial or management of the Company, group companies, associated companies, or any persons that may have a conflict of interest resulting in they cannot giving an independent opinion.The business relationship, according to the first paragraph, includes normal business transactions, lease or lease out of the property, the transaction relating to an asset or service, or provision or acceptance of financial support through lending or borrowing, provision of guaranty, provision of security for obligations, and any other similar transactions, which create obligations to the Company or its counterparty in the amount of 3% of the net tangible assets of the Company or THB 20 million and above, whichever amount is lower. The calculation of such obligations shall be under the calculation methods for related party transactions prescribed under the Notification of the Capital Market Supervisory Board relating to related party transactions, mutatis mutandis. However, in calculating such obligations, any obligations which arise one year before the entry into the business relationship with the same person shall be incorporated.

  5. Not being or was an auditor of the Company, parent company, subsidiary companies, associated companies, major shareholders, controlling persons of the Company or juristic persons that may have a conflict of interest and not being significant shareholder, the controlling person, managing partner of an audit firm of the auditor of Company, parent company, subsidiary companies, associated companies, major shareholders, controlling persons of the Company unless they have been discharged from such a position for not less than two years before being appointed as a member of the Audit Committee.

  6. Not being or was a professional advisor, including providing legal advice service or financial advisor service which receives service fees greater than two million THB per year from the Company, parent company, subsidiary companies, associated companies, major shareholders, controlling persons of the Company, and not being significant shareholder, controlling person or managing partner of such professional advisor unless they were discharged from such a position for not less than two years before being appointed as a member of the Audit Committee.

  7. Must not be a director who acts as a representative for protecting the benefit of the Company’s directors, crucial shareholders, or shareholders who have a relationship with crucial shareholders. In addition, they shall provide recommendations or report independently, as assigned, without consideration of any benefits that may limit them in providing an independent opinion.

  8. Not undertaking any business in the same nature and in significant competition to the business of the Company or subsidiaries or not being a partner in a partnership or being an executive director, employee, staff, advisor who receives salary or holding shares exceeding 1 % of the total number of shares with voting rights of other company which undertakes business in the same nature and in significant competition to the business of the Company or subsidiaries.

  9. Must not have any characteristic which makes them incapable of expressing independent opinions concerning the Company’s business.

  10. The Audit Committee shall be the independent director of the Company which qualifies pursuant to the regulations of the Office of the Securities and Exchanges Commission (“SEC”).

After being appointed as the independent director which has the qualifications as set out in Clause 1) to Clause 10). Herein, the independent director may be assigned by the Board of Directors to make any decision on the business operation of the Company, subsidiaries, associated companies, subsidiaries at the same level, a juristic person that may have a conflict of interest, major shareholder, controlling person whereby the making decision shall be exercised as the collective decision.

Did Any Independent Director Have a Business or Professional Relationship?

No

Director Development

Development of Directors in the Past Year

Director Development

The Company requires a new director orientation every time and to have director’s manual, useful information for directors including a lecture on the Company's business to build up knowledge and understanding of business and operations, as well as policies and guidelines for corporate governance principles of the Company. In 2025, there was an orientation for new directors and existing directors totaling 6 directors, namely 1) Mr.Paiboon Eksaengsri, (M.D.), 2) Mr.Sam Tanskul, 3) Mr.Paradorn Leosakul, 4) Ms.Sutida Mongkolsuthree, 5) Mr.Siripong Luengvarinkul, and 6) Mr.Pramuk Unachak, (M.D.)

The Company wishes the directors to develop their knowledge and skills in the performance of duties regarding the business of the company, corporate governance principle and other training courses that are useful for the duties. The Company encourages the directors to attend training courses held by the Thai Institute of Directors and other institutions in the relevant courses.

In 2025, the Company has promoted directors to attend seminars and training programs of Thai Institute of Directors, the Stock Exchange of Thailand or other independent organizations, as follows;

Directors

Courses / Seminars in 2025

Organized by

1. Mr. Aurchat Kanjanapitak, (M.D.)

None

2. Mr. Tanatip Suppradit, (M.D.)

None

3. Mr. Paiboon Eksaengsri, (M.D.)

  • Director Accreditation Program (DAP), On 19 – 20 August 2025

IOD

  • Director Certification Program - (DCP), On 8 September – 6 October 2025

IOD

  • ESG101 Fundamentals of Sustainability Knowledge,
    On 2 December 2025

SET

4. Mr.Chalermkul Apibunyopas

  • ESG101: Fundamentals of Sustainability Knowledge,

    On 11 September 2025

SET

  • BHR101: Introduction to Human Rights due Diligence, On 11 September 2025

SET

  • CFO01: Business and GHG Emission Reduction, On 11 September 2025

SET

  • CE102: How to be a zero-waste office?, On 12 September 2025

SET

5. Mr.Siripong Luengvarinkul, (M.D.)

None

6. Mrs.Kannika Ngamsopee

  • Insight in SET: ID & AC Focus

    On 19 November 2025

SET

7. Mr.Virachai Srikajon

None

-

8. Mr.Paradorn Leosakul

  • Certificate Program in Medical Governance for Executives (Batch 12). On 17 October 2025 - September 2026

    (11-Month Course)

Medical Council of Thailand

9. Dr.Vikrom Koompirochana

None

-

10. Ms.Sutida Mongkolsuthree

None

-

11. Dr. Rukkagee kanjanapitak

  • Certificate Program in Medical Law, Class of 1, The Medical Council of Thailand, On 16 December 2024 – 24 March 2025

Medical Council of Thailand

12. Mr.Sita Meksawan

None

-

13. Prof. Dr..Aasis Unnanuntana

  • ESG101: Fundamentals of Sustainability Knowledge,

    On 8 December 2025

SET

  • BHR101: Introduction to Human Rights due Diligence,
    On 30 December 2025

SET

  • Attended a seminar for the Executive Committee of the Osteoporosis Foundation of Thailand,
    On 17 – 19 January 2025

TOPF

  • Prince Mahidol Award Conference 2025 “Harnessing Technologies in an Age of AI to Build a Healthier World”, On 31 January – 2 February 2025

Mahidol University

  • Presented research and participated in the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO-IOF-ESCEO 2025),
    On 10-13 April 2025

IOF and ESCEO

  • Speaker at the 8th CAOS (Computer Assisted Orthopaedic Surgery) Thailand Annual Meeting 2025,
    On 8 - 9 May 2025

RCOST

  • Presented research and became a member of Association of Bone and Joint Surgeons (ABJS), received an official certificate from Amy L. Ladd, MD (The 76th ABJS President 2024-2025, The 77th ABJS 2025 Annual Meeting, On 14 – 18 May 2025

ABJS

  • Speaker at the Osteoporosis Training Course 2025,
    On 24 - 25 May 2025

TOPF

  • Participated in a seminar, “Expert Meeting Teriparatide in Men and GIOP Indications”, On 28 June 2025

Zuellig Pharma

  • Speaker at the Joint Conference in Medical Sciences 2025:
    Chula-Rama-Siriraj-Thammasat, On 23 - 25 July 2025

4 Medical Sciences namely,

Chulalongkorn University / Ramathibodi Hospital, Mahidol University / Siriraj Hospital, Mahidol University / and Thammasat University

  • Speaker at an academic conference, “Together for Access: Advancing Healthcare through Biosimilars”, On 25 July 2025

Sandoz (Thailand) in collaboration with the Rheumatism Association of Thailand

  • Speaker at the SEA & HK Bone Academy “STRONGER FOUNDATIONS, EMPOWERED PRACTICE: Improving bone health through evidence and collaboration”, On 2 – 3 August 2025

Amgen (Thailand) Co., Ltd.

  • Speaker at the Amgen Bone Night 2025, On 5 August 2025

Amgen (Thailand) Co., Ltd.

  • Participated in an academic conference “Sandoz Expert Input Forum for Osteoporosis”,

    On 29 August 2025

Sandoz

  • Participated in postgraduate seminar, Department of Orthopaedic Surgery and Physical Therapy, On 7 - 8 September 2025

Faculty of Medicine, Siriraj Hospital, Mahidol University

  • Attended the Board meeting No.10/2025 of the Hip and Knee Surgeons Association of Thailand, term 2024-2026,
    On 18 September 2025

Hip and Knee Surgeons Association of Thailand

  • Speaker at the International Conference, the 9th Asian Federation of Osteoporosis Societies Congress (AFOS 2025) & the 20th Thai Osteoporosis Foundation Annual Conference

    On 25 - 27 September 2025

TOPF

  • Speaker at an academic seminar, Round Table Discussion and Medical Advisory Board Meeting

    On 30 September 2025

Abbott Laboratories Co., Ltd.

  • Participated in the 13th Fragility Fracture Network Global Congress 2025, On 1 - 4 October 2025

Fragility Fracture Network (FFN)

  • Speaker at an academic seminar, the 47th Annual Meeting of the Royal College of Orthopaedic Surgeons of Thailand (RCOST 2025), On 22 - 25 October 2025

RCOST

  • Speaker at an annual academic seminar, the 36th TASP Annual Scientific Meeting 2025 on “The Sum of All Pain”

  • On 6 - 8 November 2025

Pain Study Association of Thailand

  • Participated in the New Era in NCD Management: Advancing Outcomes through Integrative Obesity Science, On 7 November 2025

Zuellig Pharma

  • Speaker at an academic seminar, the 17th Annual Meeting on Orthogeriatrics and Metabolic Bone Disorder 2025, On 13 – 14 November 2025

RCOST

  • Attended the Board meeting of Thailand Osteoporosis Foundation, TOPF Open House,

    On 1 December 2025

TOPF

  • Speaker at an academic seminar, the 27th annual meeting of the Thai Hip and Knee Society (THKS) in collaboration with the Stanford Department of Orthopaedic Surgery “THKS x Stanford 2025”, On 4 - 6 December 2025

THKS

14. Dr.Kajorn Thanapase

None

-

15. Mr.Pramuk Unachak, (M.D.)

  • Director Accreditation Program (DAP), On 18 - 19 September 2025

IOD

  • Ethical Leadership Program (ELP)

    On 17 November 2025

IOD

16. Ms. Nalin Vanasin

None

-

17. Mrs. Charuvarn Vanasin

None

-

Evaluation of Board & Subcommittee Performance

Criteria for Evaluating Board Performance

Self-Assessment of the Board of Directors, Sub-committees, and individual directors’ performance

The Company has organized the performance assessment of the Board of Directors every year at least once a year by using the guideline in accordance with self-assessment form of the Stock Exchange of Thailand to improve to in line with the charters of each committee of which it shall be used as the framework to review the performance, problem and difficulty that occurred in the previous year and to improve the performance.

Performance Assessment Method

  1. The Company Secretary provides the self-assessment form to the Company’s director by position and duty divided into 3 categories:

1.1 Performance Assessment Form of the entire Board of Directors

1.2 Performance Assessment Form of each Sub-committee

1.3 Performance Assessment Form of the individual director

  1. The Company’s director shall complete the assessment form and return the completed form to the Company Secretary. For the assessment of individual director, the Company Secretary shall collect and separate into 2 parts by the following:

2.1 The Assessment Form of each member of the Nomination and Remuneration Committee shall be provided to the Chairman of the Board of Director for review before delivery to the Company Secretary to summarize the result. 2.2 The Assessment Form of individual director of other directors shall be provided to the Nomination and Remuneration Committee for review before delivery to the Company Secretary to summarize the result.

  1. The Company Secretary shall summarize the results of an assessment of the Company’s directors and shall report such result to the Board of Directors for acknowledgment to disclose in the annual report and disclosure system of the Company.

Criteria of Performance Assessment

Criteria

Entire Board of Directors

Each Sub-committee

Individual Director

(1) Board structure and qualifications

Yes

Yes

Yes

(2) Roles, duties and responsibilities of the board

Yes

Yes

Yes

(3) The board meeting

Yes

Yes

Yes

(4) Duties of Directors

Yes

No

No

(5) Relationship with management

Yes

No

No

(6) Director‘s self-improvement and management training

Yes

No

No

The result of assessment form in 3 categories can be divided into 4 levels as follows:

0: Strongly disagree or never conducted

1: Disagree or seldom conducted

2: Fair or moderately conducted

3: Agree or well conducted

4: Strongly agree or excellently conducted

Evaluation of Board Performance in the Past Year

Summary of the assessment of each committee in 2025 as follows:

Evaluation Results

Evaluated BodyGroup — Carried Out?Group — Grade / Average ScoreGroup — Grade / Full ScoreIndividual (Self-Assessment) — Carried Out?Individual (Self-Assessment) — Grade / Average ScoreIndividual (Self-Assessment) — Grade / Full ScoreCross (Assessing Other Directors) — Carried Out?
Board Of DirectorY3.614Y3.544N
Audit CommitteeY3.784NN
Other SubcommitteeY3.734NN
Other SubcommitteeY3.784NN
Other SubcommitteeY44NN

Subcommittees

Subcommittees

Results of the Subcommittee's Duty Performance

The sub-committees have performed their duties according to the charter of each committee and regularly reported summaries to the Board of Directors. The report of the Corporate Governance and Sustainability Committee for the year 2025 is provided in Attachment 7.

The sub-committees have performed their duties according to the charter of each committee and regularly reported summaries to the Board of Directors. The report of the Risk Management Committee for the year 2025 is provided in Attachment 9.

The sub-committees have performed their duties according to the charter of each committee and regularly reported summaries to the Board of Directors. The report of the Nomination & Remuneration Committee for the year 2025 is provided in Attachment 8.

Meeting Attendance & Remuneration

Justification for Directors' Non-Attendance

In 2025, there were a total of 5 ad hoc Board of Directors’ meetings convened on an urgent basis, besides the regularly scheduled meetings set in advance for the year. 3 directors, namely 1. Ms. Sutida Mongkolsuthree, 2. Mr. Paradorn Leosakul, and 3. Prof. Dr. Aasis Unnanuntana, had prior commitments that had already been scheduled. Therefore, they were unable to attend these urgent meetings.

Types of Remuneration of the Board of Directors

    The 2025 Annual General Meeting of Shareholders held on 23 April 2025 approved the monetary remuneration of the directors and subcommittee as follows:

1) Monetary remuneration to directors

    1.1    Annual Remuneration: Pay to only the Chairman or the Company’s directors who are not executives, and Chairman or sub-committee members who are not executives at the prescribed rate    

    1.2    Meeting Allowance: Pay at the rate of Baht 15,000 /meeting only to the Chairman or the Company’s directors who are not executives, and Chairman or sub-committee members who are not executives, who attend the meeting

    The annual remuneration rates and meeting allowances for the Board of Directors and Sub-committees for the year 2025 as follows: 

Committee / Position

2025

Annual Remuneration    

Meeting Allowance    

(Baht/year)

(Baht/ time)

The Board of Directors

Chairman of the Board (Non-executive)    

300,000

15,000    

Director (Non-executive)    

150,000

15,000    

Director (Executive)    

None

None    

Subcommittee

The Audit Committee

Chairman of the Subcommittee (Non-executive)    

250,000

15,000

Director (Non-executive)    

100,000

15,000

Director (Executive)    

None

None

The Risk Management Committee    

Chairman of the Subcommittee (Non-executive)    

200,000

15,000

Director (Non-executive)    

100,000

15,000

Director (Executive)    

None

None

The Nomination and Remuneration Committee    

Chairman of the Subcommittee (Non-executive)    

150,000

15,000

Director (Non-executive)    

100,000

15,000

Director (Executive)    

None

None

The Corporate Governance and Sustainability Committee    

Chairman of the Subcommittee (Non-executive)    

100,000

15,000

Director (Non-executive)    

100,000

15,000 

Director (Executive)    

None

None

Remarks:    

1) The Executive Committee is not a subcommittee; therefore, is not entitled to any remuneration.

2) Chairman and all committee members that are executives are not entitled to any remuneration.

   

    In 2025, the payment of remuneration to directors namely retirement allowance and meeting allowance (directors’ meeting allowance, shareholders’ meeting allowance and independent directors’ meeting allowance), subcommittee meeting’s fee and annual remuneration for directors and subcommittee. The total amount is 7,210,958.91 baht and no accrued expenses from the previous year.

2) ther Remunerations

    2.1 Medical allowances in 1) Thonburi Hospital; 2) Thonburi Thawiwatthana Hospital; and 3) Thonburi Bamrungmuang Hospital in 2025 are as follows:

Position

Medical Allowances for 2025

Chairman and Directors    

Baht 150,000 per year with 50% discount in excess amount    

Parents    

50% discount with unlimited amoun

Spouse and minor child    

    2.2    Directors’ and officers’ liability insurance    

    In 2025, the Board of Directors received compensation for medical services totaling THB 5,605,564.46

Remuneration or Benefits Payable to the Board

MetricAmount (Baht)
Remunerations or benefits pending payment to the board of directors over the past year (baht)0

Supervision of Subsidiaries & Associated Companies

Does the Company Have Subsidiaries or Associated Companies?

Yes

Is There a Mechanism for Overseeing Subsidiaries and Associated Companies?

Yes

Mechanism for Overseeing Management of Subsidiaries

Supervision of operations of subsidiaries and associated companies  

The Company has a mechanism to supervise the operations of its subsidiaries and associated companies to monitor benefits from the Company’s investments as follows:

  • The proportion of directors and/or executives in subsidiaries and associated companies nominated by the Company shall not be less than the Company’s respective shareholding in subsidiaries and associated companies.

  • Governance, authority, roles and responsibilities of representative directors shall adhere to the management policy and the financial control policy of the Company’s subsidiaries and associated companies. Voting on important resolutions shall be in accordance with the Company’s approval authority. It also requires that representative directors regularly report information related to various transactions from subsidiaries to the Executive Committee meeting for acknowledgment, and in case of important matters, the Executive Committee meeting shall report them to the Board of Directors meeting for their information as well.

  • Subsidiaries are required to submit annual budget and business plan to the Company for approval. The operating performance of subsidiaries shall be reported on a quarterly basis. The Company may request subsidiaries to provide clarifications or request additional information from subsidiaries when needed.

  • The Board of Directors has appointed directors and/or executives as directors in subsidiaries, associated companies, and joint venture companies. In case any representative director and/or executive resigns, the Board of Directors will consider appointing another director and/or executive to monitor interests on behalf of the Company according to the shareholding proportion by the Company.

  • The roles and duties of representative directors and executives have been emphasized to comply with rules and approval authorities. Additionally, there is training for directors, executives, and relevant employees to raise awareness about compliance with the company's rules and internal regulations, as well as the consequences of non-compliance with such rules and regulations.

  • Balance of payment authorization power by requiring that all disbursements for the entire group of companies must be approved by at least 2 people, in line with authorized signatory directors, as well as reviewing bank transfer reports on a monthly basis.

  • Preparing internal audit plans and reviewing the internal control system by considering internal audit findings of control systems and all aspects of risk assessment, as well as management opinions in determining internal audit plans for various systems. There is also quarterly monitoring of internal audit reports from subsidiaries that are in preparation for initial public offering and stock exchange listing (IPO) that have an in-house Internal Audit department and/or have hired external Internal Audit services (Outsource IA).

  • For whistleblowing and complaints, there is a scheduled agenda item for reporting whistleblowing and complaints in Executive Committee meetings and subsidiary Board of Directors meetings, as well as emphasizing that executives of each company should communicate this to employees regularly.

Oversight Mechanisms

Mechanism
Sending representatives to act as directors, executives or controlling persons in proportion to shareholdings
Defining the scope of powers, duties and responsibilities of directors and executives who represent the company in setting important policies
Disclosure of financial information and operating results
Transactions between the Company and related persons
Other important transactions
Acquisition or disposal of assets
Internal control system of the subsidiary operating the core business is appropriate and sufficient in the subsidiary operating the core business

Audit Committee Duty Performance

Results of the Audit Committee's Duty Performance in the Past Year

Report of the Audit Committee 2025

Dear Shareholders, Thonburi Healthcare Group Public Company Limited

The Audit Committee of Thonburi Healthcare Group Public Company Limited is comprised of
3 independent directors who are eminent persons and fully qualified as independent director according to
the rules prescribed by the Securities and Exchange Commission and the Stock Exchange of Thailand.
The independent directors have performed their duties with independence within the scope of duties and responsibilities of the Audit Committee as assigned by the Board of Directors. The Audit Committee consists of:

1. Mrs. Kannika Ngamsopee, Chairwoman of the Audit Committee

2. Mr. Virachai Srikajon, Member of the Audit Committee

3. Dr. Linda Kraivit ( M.D.), Member of the Audit Committee (Resigned on 31 January 2025)

4. Mr. Sam Tanskul*, Member of the Audit Committee (Appointed on 20 February 2025 and resigned on 26 November 2025)

5. Mr. Paradorn Leosakul**, Member of the Audit Committee (Appointed on 26 November 2025)

Ms. Hathaichanok Pangnoi, Director of the Internal Audit Department, is the Secretary of the Audit Committee.

* The Board of Directors’ Meeting No. 2/2025 held on 20 February 2025 resolved to appoint Mr. Sam Tansakul as a member of The Audit Committee to replace Dr. Linda Kraiwith (M.D.), who resigned on 26 January 2025.** The Board of Directors’ Meeting No. 15/2025 held on 26 November 2025 resolved to appoint Mr. Paradorn Leosakul as a member of The Audit Committee to replace Mr. Sam Tansakul, who resigned on 26 November 2025.

The Audit Committee has performed its duties according to the scope and responsibility as assigned by the Board of directors ,the Audit Committee charter and the Company regulations on rules and guidelines of the Audit Committee are in line with the regulations of the Stock Exchange of Thailand. In 2025, the Audit Committee held 11 meetings, with attendance as follows:

Name-Surname

Position

Number of meetings attended/
Meeting attendance rights

  1. Mrs. Kannika Ngamsopee

Chairwoman of the Audit Committee

11 / 11

  1. Mr. Virachai Srikajon

Member of the Audit Committee

11 /11

  1. Dr. Linda Kraivit (M.D.)

Member of the Audit Committee

2 / 2

  1. Mr. Sam Tanskul

Member of the Audit Committee

8 / 8

And the meetings were held with relevant executives, auditors, and internal auditors. The significant points can be summarized as follows:

  1. Review of Financial Reports: The Audit Committee reviewed the quarterly financial statements and the related financial statements for 2025. The transaction may be conflict of interest, inviting relevant executives and auditors to attend the meeting to clarify and answer the questions of the Audit Committee. The accuracy and completeness of any significant accounting changes affecting the financial statements have been included in the consolidated financial statements. The adequacy of information disclosed in the financial statements and the auditor's remarks. The Audit Committee is of the opinion that the financial statements have been properly disclosed in accordance with the financial reporting standards. The Audit Committee provided observations and recommendations regarding financial risk issues, which have been duly addressed by the Company. In addition, the Audit Committee held meetings with the auditors without the management to discuss with the auditor on matters relating to accounting and financial reporting. The Audit committee has good cooperation with management, be independent in the work as well as knowledge the experience and guidelines for reviewing or reviewing the financial reports are adequate and appropriate for the performance of the auditor's duties

  2. Review of Internal Control System and Risk Assessment: The Company reviewed the internal control system of the Company according to the assessment of the adequacy of the internal control system for 2025. During the Board of Directors’ Meeting No. 2/2026, held on 23 February 2026, the Company’s internal control system in respect of 5 elements was evaluated. The Board of Directors is of the opinion that the Company's internal control system is adequate and appropriate.

    In cases where the Audit Committee identifies issues significant weaknesses or deficiencies were identified, the Audit Committee will informed the management to implement corrective actions and will monitor the progress of such improvements. Internal Audit Department has also followed up on the corrective actions relating to internal control and corporate governance matters of the Company and its subsidiaries identified in 2024. Such matters have already been improved, including the clarification of the roles and responsibilities of directors and management representatives, such as the roles and duties of directors and executive representatives, clear guidelines for reporting by directors or executive representatives appointed to positions in subsidiaries, and checks and balances in financial transactions. and the reinforcement of whistleblowing and complaint mechanisms.

  3. Oversight of Internal Audit: The Audit Committee has approved the scope of work Internal Audit and Internal Audit Plan for 2025. In the year 2025, The Company maintained internal audit team and engaged an internal audit outsource service provider to ensure that the audit activities adequately covered key operational systems of the Company and its subsidiaries, reviewed and evaluated the system of Internal control of the Company and subsidiaries by considering of Internal audit report, following up the corrective action according to the internal audit report, the company's and providing advice on how to improve the performance of Internal audit, providing information on independence of the Internal Audit Department as well as providing advices on appropriate budget, manpower, training, personnel development and the Performance Appraisal of Head of Internal Audit Department. Following the suspicious transactions that occurred in the subsidiaries, The Audit Committee is of the opinion that the Company has an appropriate and effective internal audit system.

  4. Compliance with Securities and Stock Exchange of Laws, Regulations of the Stock Exchange of Thailand and/ or Other laws related to the Company’s business : The Audit Committee has reviewed the operations of the Company to ensure compliance with Securities and Exchange laws, the regulations of the Stock Exchange of Thailand, and/or laws related to the Company's business, including compliance with the Company's requirements and obligations that the Company has with external parties. The Audit Committee is of the opinion that it is complied with the Securities and Exchange Act, the Stock Exchange of Thailand, and/or laws related to the Company’s business

  5. Review of Connected Transactions or Possible Conflicting Interest Transactions to Ensure Compliance with the Law and Stock Exchange of Thailand’ s Regulations: The Audit Committee reviewed and provided opinions on connected transactions or transactions that may have conflicts of interest, including the disclosure of such transactions, in accordance with the regulations of the Stock Exchange of Thailand and the Office of the Securities and Exchange Commission. The Audit Committee has agreed with the auditor. They also commented that significant items were disclosed and presented in the financial statements. The note to the financial statements are accurate and complete.

  6. Risk Management: There is the Risk Management Committee which is responsible for formulating rules, policies, and procedures for assessing and managing risks that affect the Company, reviewing the risk management system including reporting to the Audit Committee and the Board of Directors on strategic risk management, financial report, performance and compliance with relevant rules and laws. The Audit Committee is responsible for reviewing and monitoring the risk management plan of the business group including the risk of events which may have significant changes that affect the Company's operations, such as risks of core business, risk from investment in projects in both the domestic and international countries, etc. The Audit Committee is of the opinion that the Company has complied with an effective risk management system.

  7. Appointment of the Auditors for the year 2026: The Audit Committee has considered the appointment of the auditors and audit fees to propose to the Board of Directors and the annual shareholders' meeting for approval. After consideration of the qualifications, abilities of the auditors, performance, independence and appropriateness of the audit fee, the Audit Committee has proposed to appoint PricewaterhouseCoopers ABAS Co., Ltd. to be the Company's auditor for the year 2026 with the following name of auditors: Ms. Sanicha Akarakittilap (CPA No. 8470) or Ms. Nopanuch Apichatsatien (CPA No. 5226) or Ms. Yuwanan Manomivisit (CPA No. 9804) for the fiscal year ending 31 December 2026. All the auditors are auditors approved by the Securities and Exchange Commission, which have adequate knowledge and experience.

  8. Others: The Audit Committee reviewed the charter to ensure its suitability and compatibility with Stock Exchange of Thailand announcement on the qualifications and work scope of Audit Committees B.E. 2558 (2015) and Audit Committee Manual B.E. 2553 (2010) and Best Practice Guidelines for Audit Committee to prevent and suppress inappropriate behavior of listed companies B.E.2566(2023). The Audit Committee has reviewed the Audit Committee Charter the amendment to the 3rd, effective on 25 June 2025, The Audit Committee is of the opinion that to be appropriate and in accordance with the announcement of the Stock Exchange of Thailand.

    From the performance of the Audit Committee's duties during the year 2025, as reported above, the Audit Committee has made observations regarding suspicious transaction issues with the management and has provided recommendations to improve the internal control system and governance of subsidiaries to elevate the company to have good corporate governance, sufficient and appropriate internal controls for business operations, effective risk management and internal audit systems. The accounting system and financial reports are accurate and reliable, in accordance with generally accepted accounting standards, as well as continuous compliance with laws, regulations, and rules related to the company's business operations.
    Throughout the year 2025, the Audit Committee has carried out the duties successfully, thanks to the strong cooperation and support from the Board of Directors, executives, auditors, and all relevant parties.
    On this occasion, we would like to extend our sincere appreciation and gratitude to everyone involved for their valuable contributions and collaboration.

On behalf of the Audit Committee

-Mrs. Kannika Ngamsopee-

Chairwoman of the Audit Committee

Executive Committee Duty Performance

Results of the Executive Committee's Duty Performance in the Past Year

-

Contents